Page 101 - MEMORIA_SEHH-FEHH_2023

MEMORIA ANUAL 2023
SOCIEDAD ESPAÑOLA DE
HEMATOLOGÍA Y HEMOTERAPIA
PETHEMA
FUNDACIÓN ESPAÑOLA DE
HEMATOLOGÍA Y HEMOTERAPIA
• Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different
expression patterns from those revealed by gene expression profiling.
Haematologica. 2023. doi: 10.3324/haematol.2023.283445.
Cardona-Benavides IJ, Misiewicz-Krzeminska I, Rojas EA, De Ramón C, Sanz-Solas A,
Isidro I, Quwaider D, López-Guerrero AM, Cuadrado M, Calasanz MJ, Rosiñol L, Martínez-
López J, San Miguel JF, Mateos MV, Corchete LA, Gutiérrez NC.
• Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with
or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients.
Haematologica. 2023;108(10):2753-63. doi: 10.3324/haematol.2022.282490.
Puertas B, González-Calle V, Sureda A, Moreno MJ, Oriol A, González E, Rosiñol L, López
J, Escalante F, Martínez-López J, Carrillo E, Clavero E, Ríos-Tamayo R, Rey-Bua B, Gon-
zález-Rodríguez AP, Dourdil V, De Arriba F, González S, Pérez-de-Oteyza J, Hernández
MT, García-Mateo A, Bargay J, Bladé J, Lahuerta JJ, San Miguel JF, Ocio EM, Mateos MV.
• First-line treatment of multiple myeloma in both transplant and non-transplant can-
didates.
Expert Rev Anticancer Ther. 2023;23(7):685-98. doi: 10.1080/14737140.2023.2213891.
Oriol A, Abril L, Ibarra G.
• Genetic variants of CTLA4 are associated with clinical outcome of patients with
multiple myeloma.
Front Immunol. 2023;14:1158105. doi: 10.3389/fimmu.2023.1158105.
González-Montes Y, Rodríguez-Romanos R, Villavicencio A, Osca-Gelis G, González-Bár-
tulos M, Llopis F, Clapes V, Oriol A, Sureda A, Escoda L, Sarrà J, Garzó A, Lloveras N, Díez
I, Granada I, Gallardo D.
• Lenalidomide maintenance based on a genetic profile.
Blood. 2023;141(14):1649-50. doi: 10.1182/blood.2022019352.
Mateos MV, González-Calle V.
• Multiple myeloma with t(11;14): impact of novel agents on outcome.
Blood Cancer J. 2023;13(1):40. doi: 10.1038/s41408-023-00807-9.
Puertas B, González-Calle V, Sobejano-Fuertes E, Escalante F, Rey-Bua B, Padilla I, Gar-
cía-Sanz R, Puig N, Gutiérrez NC, Mateos MV.
• Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple
Myeloma.
Cancers (Basel). 2023;15(5):1558. doi: 10.3390/cancers15051558.
101